Recommended

Discover the latest breakthroughs in environmental monitoring when you download our latest brand report! Get your free copy today!
Explore innovative, purpose-built AI solutions that elevate compliance and efficiency in quality and manufacturing operations.
Explore how lipid formulations in softgels can enhance drug absorption and bioavailability in this upcoming webinar!
Discover approaches to advance manufacturing processes such as continuous manufacturing, address key manufacturing challenges and optimise product quality at our upcoming webinar – Register now!
EPR’s latest Pharma Horizons report explores the latest advances in cell and gene therapy for quality control, manufacturing, analytical development and more – READ MORE
Register for this webinar to learn about impurity control in pharmaceutical waters! Coming soon!
View our brand new Guide to Testing for 2025!
news

Cabenuva (cabotegravir and rilpivirine) granted approval by Health Canada

20
SHARES

The first regulatory approval for Cabenuva (cabotegravir and rilpivirine) has been granted by Health Canada, in conjunction with use of Vocabria.

HIV virus

The first regulatory approval for Cabenuva (cabotegravir and rilpivirine) and Vocabria has been granted by Health Canada to ViiV Healthcare. 

According to the company, Cabenuva is is the first and only once-monthly, complete long-acting regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral (ARV) regimen in patients who are virologically stable and suppressed. Vocabria oral tablets are to be used for short time periods in conjunction with Cabenuva. 

Cabenuva is administered intramuscularly as two individual injections in the buttocks of patients once a month by a healthcare provider. 

 

Reserve your FREE place

 


Explore innovative, purpose-built AI solutions that elevate compliance and efficiency in quality and manufacturing operations.

17 September 2025 | 10:00 AM BST | FREE Webinar

In this webinar, find out how AI tools such as customised large language models (LLMs), orchestrated services, and human-in-the-loop design can streamline processes, enhance training, and improve efficiencies.

Don’t miss your chance to learn from industry experts – Register Now – It’s Free!

 

Deborah Waterhouse, Chief Executive Officer of ViiV Healthcare, said: “Today’s approval marks a monumental step in the treatment of HIV and is a true testament to ViiV Healthcare’s R&D innovation. With Cabenuva, people living with HIV who are virologically suppressed now have an option to maintain that suppression with 12 treatments a year, thereby positively impacting their lives.”

The approval of the drug is based on two Phase III studies that included more than 1,100 participants from 16 countries. The complete regimen combines the integrase strand transfer inhibitor (INSTI) cabotegravir, with rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) developed by Janssen. INSTIs inhibit HIV replication by preventing the viral DNA from integrating into the genetic material of T cells, a step essential in the HIV replication cycle and responsible for establishing chronic infection.

Cabotegravir and rilpivirine complete long-acting regimen for the treatment of HIV-1 infection therapy is under review by the European Medicines Agency (EMA) and regulatory authorities in Switzerland and Australia. 

Share via
Share via